Figure 2: Comparison of HFA227 formulations in terms of drug deposited on each stage of Next Generation Impactor, maintaining constant concentration of ethanol (data represent mean ± SD, ). MOC: microorifice collector. * (ANOVA/Tukey’s) 5.45% w/w Pluronic L81 versus 0 and 1.22% w/w Pluronic L81, ** (ANOVA/Tukey’s) comparing all formulations, (ANOVA/Tukey’s) 1% w/w Pluronic L81 versus 0 and 5% w/w Pluronic L81, and ^{#} (ANOVA/Tukey’s) 0% w/w Pluronic L81 versus 1.22 and 5% w/w Pluronic L81.